These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16258427)

  • 1. mTOR inhibitors in hematologic malignancies.
    Dancey JE
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S; Houghton PJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies.
    Altman JK; Platanias LC
    Curr Opin Hematol; 2008 Mar; 15(2):88-94. PubMed ID: 18300753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
    MacKenzie AR; von Mehren M
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
    Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.
    Decker T; Sandherr M; Goetze K; Oelsner M; Ringshausen I; Peschel C
    Ann Hematol; 2009 Mar; 88(3):221-7. PubMed ID: 18704419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrotoxicity of sirolimus: experimental and clinical data].
    Pallet N; Thervet E; Legendre C; Anglicheau D
    Nephrol Ther; 2006 Sep; 2(4):183-90. PubMed ID: 16966063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
    Cruzado JM
    Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mammalian target of rapamycin (mTOR) for health and diseases.
    Tsang CK; Qi H; Liu LF; Zheng XF
    Drug Discov Today; 2007 Feb; 12(3-4):112-24. PubMed ID: 17275731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR and cancer therapy.
    Easton JB; Houghton PJ
    Oncogene; 2006 Oct; 25(48):6436-46. PubMed ID: 17041628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin inhibition.
    Dutcher JP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6382S-7S. PubMed ID: 15448035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.